Arcadia Biosciences Inc

Arcadia Biosciences Inc(RKDA)股票分析

$0.161

-0.006 (-3.59%)收盘时

Loading chart…
最高
0.167
开盘
0.159
成交量加权均价
0.16
成交量
173.13K
市值
4.25M
最低
0.156
成交额
27.91K
企业价值/息税折旧摊销前利润(TTM)
1.43

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

AI 分析 of Arcadia Biosciences Inc (RKDA)

卖出

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

分析师评级(1)

持有
0 买入
1 持有
0 卖出
当前: 0.16
最低
—
平均
—
最高
—

HC Wainwright & Co.

2024-08-21

目标价

$6

强烈买入

HC Wainwright & Co.

2024-05-23

目标价

$6

强烈买入

HC Wainwright & Co.

2024-04-05

目标价

$10

强烈买入

HC Wainwright & Co.

2023-08-28

目标价

$10

强烈买入

HC Wainwright & Co.

2023-07-24

目标价

$15

强烈买入

估值指标

Arcadia Biosciences Inc(RKDA)当前预期市盈率为 36.63,5 年平均预期市盈率为 5.54。

预期市盈率

严重高估
5 年均值 P/E
5.54
当前P/E
36.63
高估
20.96
低估
-9.87

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
0.43
当前EV/EBITDA
1.43
高估
1.19
低估
-0.34

预期市销率

低估
5 年均值 P/S
0.85
当前P/S
0.05
高估
1.43
低估
0.26

Alphio AI 对 RKDA 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%RKDA

$5.40

情景价格

基

基准

基准 · 50%RKDA

$5.18

情景价格

悲

悲观

悲观 · 25%RKDA

$5.10

情景价格

事件时间线

2026-06-26 (ET)

17:00:00

Arcadia Biosciences Files to Sell 11.92M Shares of Common Stock

2026-06-11 (ET)

21:00:00

Arcadia Biosciences Sells 3,883,496 Shares at $1.03 Each

2026-01-28 (ET)

06:10:00

Arcadia Biosciences Files to Sell 1.67M Shares of Common Stock

2026-01-20 (ET)

06:10:00

Rockwell Medical Sees Q4 Gross Margin Rise to 22%

2026-01-12 (ET)

08:50:00

Arcadia Biosciences Issues Preferred Investment Options, Raises Approximately $2.1M

资讯

RKDA 常见问题 —— 由 Alphio AI 解答

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour. It operates in the Consumer Non-Cyclicals sector.

Arcadia Biosciences Inc (RKDA) is not a good buy right now due to its current price of $0.16, a year-to-date change of -92.52%, and a concerning forward P/E ratio of 36.63, indicating potential overvaluation despite the low stock price. The company is facing significant financial challenges, including a recent report of a Q4 GAAP EPS of -$0.97 and a revenue decline of 26.2% year-over-year, which raises serious doubts about its future profitability and growth potential.

1 analysts cover RKDA: 0 rate it Buy, 1 Hold and 0 Sell.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易